AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

While Humira's sales volumes have increasingly shifted to other drugs over successive quarters this year, that has also ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...